We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 165

New Jersey Court Invalidates Regulation Defining ‘Simple Misconduct’ Under Unemployment Law
  • Ogletree Deakins
  • USA
  • September 6 2017

The Superior Court of New Jersey, Appellate Division, recently invalidated a regulation of the New Jersey Unemployment Compensation Act (UCA) that

FLH Successfully Defends Shire’s Patents Covering Blockbuster Drug Vyvanse
  • Haug Partners LLP
  • USA
  • August 30 2016

On August 30, 2016, Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey entered a Final Judgment ending a Hatch-Waxman

Bailey v. Wyeth, Inc. and Deboard v. Wyeth, Inc. - New Jersey Product Liability Act’s presumption that FDA-approved warnings are adequate
  • Sills Cummis & Gross PC
  • USA
  • October 27 2011

After more than three years, the New Jersey Appellate Division affirmed a very important trial court decision dismissing two cases in the New Jersey Hormone Replacement Therapy (“HRT”) litigation.

Big win for drug companies under the New Jersey Product Liability Act
  • Duane Morris LLP
  • USA
  • October 4 2011

On September 29, 2011, in Bailey v. Wyeth, et al., a New Jersey appellate court affirmed summary judgment in favor of two Pfizer subsidiaries and Wyeth, Inc., dismissing claims for violations of New Jersey's Product Liability Act (PLA).

Generic pharmaceutical exclusivity period ends with patent expiration
  • Oblon
  • USA
  • July 22 2011

On July 6, the New Jersey District Court filed an opinion denying the injunctive relief sought by Nostrum Pharmaceuticals LLC regarding the FDA’s decisions on the statutory exclusivity period for Nostrum’s ANDA on carbamazepine 300 mg extended-release capsules.

New Jersey retroactively levies rebate payment obligations on non-participating pharmaceutical manufacturers under the WorkFirst New Jersey General Public Assistance Act
  • Lowenstein Sandler LLP
  • USA
  • April 15 2011

The Commissioner of the New Jersey State Department of Human Services (the "State") is seeking to retroactively recoup rebates that the State claims are owed for prescription benefits provided under the WorkFirst New Jersey General Public Assistance Program from non-participating pharmaceutical manufacturing companies.

Defense verdict for Merck in first FOSAMAX state court trial
  • Locke Lord LLP
  • USA
  • February 16 2011

A New Jersey state court jury recently found in favor of Merck & Co., Inc. rejecting the claims of a woman who alleged that her dental and jaw related problems were caused by the osteoporosis drug FOSAMAX.

Court must examine totality of the evidence in deciding employer’s fee-shifting application
  • Ogletree Deakins
  • USA
  • December 22 2010

The Appellate Division recently ruled that a court must review all available evidence when determining whether a plaintiff’s lawsuit is frivolous because it is based on fabricated facts.

A tale of two cases: the extent to which a New Jersey trial court disregarded a Florida appellate court’s decision and the continued viability of the learned intermediary doctrine in New Jersey
  • Sills Cummis & Gross PC
  • USA
  • August 26 2010

Can a New Jersey trial court, applying the law of another jurisdiction, disregard an intermediate appellate decision from that other jurisdiction that is directly on point?

Pharmaceutical sales representatives not entitled to overtime pay under FLSA's administrative exemption
  • Ogletree Deakins
  • USA
  • August 6 2010

In the first of two overtime cases decided in New Jersey in July, the federal district court determined that several former pharmaceutical sales representatives are “administrative” employees and thus exempt from the overtime pay requirements of the Fair Labor Standards Act (FLSA).